Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
When examining the evolution of treatment resistance in breast cancer, perceived genomic changes may be due to clonal evolution or heterogeneous tumors. Here, the authors show that apparent clonal change can in fact be due to pre-treatment heterogeneity, and samples from at least two regions are nec...
Enregistré dans:
Auteurs principaux: | Jennifer L. Caswell-Jin, Katherine McNamara, Johannes G. Reiter, Ruping Sun, Zheng Hu, Zhicheng Ma, Jie Ding, Carlos J. Suarez, Susanne Tilk, Akshara Raghavendra, Victoria Forte, Suet-Feung Chin, Helen Bardwell, Elena Provenzano, Carlos Caldas, Julie Lang, Robert West, Debu Tripathy, Michael F. Press, Christina Curtis |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3b5c30a996d54c2086cfff5a285a1014 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
par: Jennifer L. Caswell-Jin, et autres
Publié: (2019) -
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
par: Sara A. Hurvitz, et autres
Publié: (2020) -
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
par: Advani P, et autres
Publié: (2015) -
Current neoadjuvant treatment options for HER2 positive breast cancer
par: Abdel-Razeq H, et autres
Publié: (2011) -
Impact of Intervention Measures on MRSA Clonal Type and Carriage Site Prevalence
par: Marco Cassone, et autres
Publié: (2016)